Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Investment analysts at HC Wainwright increased their FY2026 earnings estimates for shares of Alto Neuroscience in a note issued to investors on Thursday, November 12th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($2.50) for the year, up from their previous estimate of ($2.82). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Alto Neuroscience's current full-year earnings is ($2.50) per share. HC Wainwright also issued estimates for Alto Neuroscience's Q4 2026 earnings at ($0.57) EPS, Q1 2027 earnings at ($0.64) EPS, Q2 2027 earnings at ($0.67) EPS, Q3 2027 earnings at ($0.70) EPS, Q4 2027 earnings at ($0.69) EPS, FY2027 earnings at ($2.70) EPS, FY2028 earnings at ($3.39) EPS, FY2029 earnings at ($3.46) EPS and FY2030 earnings at ($3.02) EPS.
Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its quarterly earnings results on Tuesday, November 10th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.13.
A number of other equities analysts also recently issued reports on ANRO. BTIG Research reissued a "buy" rating and set a $37.00 target price on shares of Alto Neuroscience in a research note on Wednesday, November 11th. Wall Street Zen downgraded Alto Neuroscience from a "hold" rating to a "sell" rating in a research note on Saturday, September 12th. Zacks Research upgraded Alto Neuroscience from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 20th. Wedbush upped their price objective on Alto Neuroscience from $24.00 to $26.00 and gave the stock a "neutral" rating in a report on Thursday, August 13th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Alto Neuroscience in a research report on Tuesday, October 27th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $37.88.
Read Our Latest Research Report on ANRO
Alto Neuroscience Price Performance
Shares of ANRO opened at $29.73 on Monday. Alto Neuroscience has a twelve month low of $10.80 and a twelve month high of $37.48. The stock's 50 day moving average is $26.38 and its two-hundred day moving average is $24.63. The firm has a market capitalization of $1.19 billion, a PE ratio of -12.18 and a beta of 1.42. The company has a current ratio of 18.12, a quick ratio of 18.12 and a debt-to-equity ratio of 0.04.
Insider Activity at Alto Neuroscience
In related news, CFO Nicholas Smith sold 24,056 shares of the business's stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $25.82, for a total transaction of $621,125.92. Following the sale, the chief financial officer owned 24,060 shares of the company's stock, valued at approximately $621,229.20. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 11.25% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. Sterling Capital Management LLC lifted its position in shares of Alto Neuroscience by 1,045.7% during the 3rd quarter. Sterling Capital Management LLC now owns 1,054 shares of the company's stock valued at $27,000 after acquiring an additional 962 shares during the period. Farther Finance Advisors LLC boosted its stake in shares of Alto Neuroscience by 48,581.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 5,355 shares of the company's stock worth $137,000 after acquiring an additional 5,344 shares in the last quarter. GK Wealth Management LLC purchased a new stake in shares of Alto Neuroscience during the 2nd quarter worth approximately $226,000. Empowered Funds LLC acquired a new stake in shares of Alto Neuroscience in the 3rd quarter worth approximately $299,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Alto Neuroscience in the 1st quarter worth approximately $534,000.
Alto Neuroscience News Roundup
Investors following ANRO have been watching these news items:
- Positive Sentiment: HC Wainwright lifted its estimates for FY2026 EPS to ($2.50) from ($2.82), and FY2027 EPS to ($2.70) from ($3.17). It also raised quarterly estimates for Q4 2026 and Q1–Q4 2027, with each revised forecast showing a smaller expected loss. MarketBeat article
- Positive Sentiment: The firm also improved its longer-term forecasts: FY2028 EPS to ($3.39) from ($4.00), FY2029 to ($3.46) from ($4.01), and FY2030 to ($3.02) from ($3.51). HC Wainwright reiterated its Buy rating. MarketBeat article
About Alto Neuroscience
(
Get Free Report)
Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto's approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alto Neuroscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alto Neuroscience wasn't on the list.
While Alto Neuroscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.